This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
SUMMARY
- RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) for subcutaneous (SC) administration is a coformulation of amivantamab with recombinant human hyaluronidase PH20 (rHuPH20).1
- Of the 206 patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who received RYBREVANT FASPRO in combination with LAZCLUZE (every 2 weeks [Q2W] dosing) in the PALOMA-3 study, 35% were ≥65 years of age and 9% were ≥75 years of age.2
- The safety of RYBREVANT FASPRO in combination with other antineoplastic drugs or as a single agent for its approved indications has been established in adequate and well-controlled studies of RYBREVANT intravenous (IV) in combination with other antineoplastic drugs and as a single agent.2
- Of the 421 patients with locally advanced or metastatic NSCLC who received RYBREVANT IV in combination with LAZCLUZE in the MARIPOSA study, 45% were ≥65 years of age and 12% were ≥75 years of age.
- Of the 130 patients with locally advanced or metastatic NSCLC who received RYBREVANT IV in combination with carboplatin and pemetrexed in the MARIPOSA-2 study, 40% were ≥65 years of age and 10% were ≥75 years of age.
- Of the 151 patients with locally advanced or metastatic NSCLC who received RYBREVANT IV in combination with carboplatin and pemetrexed in the PAPILLON study, 37% were ≥65 years of age and 8% were ≥75 years of age.
- Of the 302 patients with locally advanced or metastatic NSCLC who received RYBREVANT IV as a single agent in the CHRYSALIS study, 39% were ≥65 years of age and 11% were ≥75 years of age.
- No clinically important differences in safety or efficacy were observed between patients who were ≥65 years of age and younger patients who received RYBREVANT IV.2
- Of the 102 patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in the primary efficacy population who received RYBREVANT FASPRO in OrigAMI‑4 after prior platinum-based chemotherapy and an anti-PD(L)-1 antibody, 45% were ≥ 65 years of age, and 11% were ≥ 75 years of age.2
- No overall differences in efficacy were observed between patients who were ≥ 65 years of age and younger patients who received RYBREVANT FASPRO.
- There was a higher incidence of serious adverse reactions (50% vs 30%) and treatment discontinuation (26% vs 9%) in patients ≥ 65 years of age compared to younger patients, respectively.
- Please refer to RYBREVANT FASPRO product labeling for additional information.2
LITERATURE SEARCH
A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File (and/or other resources, including internal/external databases) was conducted on 02 November 2026.